American Made Pharmaceuticals Act of 2023
- Last Action
- 7/25/2024
Actions
- 2024-07-25Committee on Banking, Housing, and Urban Affairs. Hearings held. Hearings printed: S.Hrg. 118-655.
- 2023-11-15Read twice and referred to the Committee on Finance.
- 2023-11-15Introduced in Senate
CRS Summary
As of 2023-11-15 (00)
American Made Pharmaceuticals Act of 2023
This bill requires the Centers for Medicare & Medicaid Services to conduct a demonstration program that gives preference to domestically manufactured drugs under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP).
The program must be conducted in at least eight states and for at least seven years. Applicable drugs include critical drugs that are needed to respond to a public health emergency and that have a vulnerable global supply chain. Preference may take the form of reduced cost-sharing, preferential treatment on formularies, bonus payments, and other specified methods.
Cosponsors (2)
- Tom Cotton (R-AR)
- Michael Bennet (D-CO)
Subjects
- Buy American requirements
- Child health
- Congressional oversight
- Drug therapy
- Emergency medical services and trauma care
- Health care costs and insurance
- Health technology, devices, supplies
- Infectious and parasitic diseases
- Manufacturing
- Medicaid
- Medicare
- Poverty and welfare assistance
- Prescription drugs
- Public contracts and procurement
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.